Hosted on MSN2h
Breakthrough Gene Therapy OCU410 Could Save Millions from Vision Loss – Phase 2 Milestone Achieved!
Ocugen, Inc. (NASDAQ: OCGN) has announced the completion of dosing in the Phase 2 portion of its ArMaDa clinical trial for ...
ophthalmologytimes9h
Angiogenesis 2025: Encapsulated cell therapy for MacTel shows long-term efficacy in phase 3 trials
Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long ...
U.S. FDA Approves Expanded Label For Astellas' IZERVAYTM (Avacincaptad Pegol Intravitreal Solution) For Geographic Atrophy
IZERVAY dosing approved beyond 12 monthsTOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Ok ...
thecardiologyadvisor.com19h
Susvimo Approval Expanded to Include Diabetic Macular Edema
The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.
People Are Using Botox To Shrink Their Pores, But Does It Work?
Botox, an injectable skin treatment most commonly used to prevent and reduce the appearance of fine lines and wrinkles, is ...